BOUT ETF: CapForce IBD Breakout Opportunities ETF - Price, Holdings & Analysis
CapForce IBD Breakout Opportunities ETF Price Chart
Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fund characteristics, expense ratio, dividend yield, and performance metrics
Frequently Asked Questions About CapForce IBD Breakout Opportunities ETF
What is the current price of BOUT?
The latest BOUT price is $44.16. The 52-week range is $35.05–$49.41. BOUT has returned 15.8% over the past 52 weeks.
What is the expense ratio for BOUT?
BOUT's annual expense ratio is 0.80%. This represents the yearly cost of holding the fund, deducted from total returns. Compare with similar Equity ETFs in the ETF Screener.
Does BOUT pay dividends?
Yes, BOUT pays a 0.28% dividend yield. The last ex-dividend date was 2027-01-02. View full dividend history in the Dividends section.
What are the top holdings of BOUT?
BOUT's largest holdings are U.S. Bancorp (7.0%), Apogee Therapeutics, Inc. (7.0%), Bicara Therapeutics Inc. (7.0%) (combined weight: 21.0%). The fund holds 28 total positions. View the complete portfolio breakdown in the Holdings section.
How does BOUT compare to similar ETFs?
Compare BOUT (0.80% expense ratio, $16M AUM) against similar Equity ETFs using the ETF Screener. Filter by expense ratio, dividend yield, and performance to find alternatives.